| Seroconversion rates following COVID-19 vaccination among patients with cancer A Thakkar, JD Gonzalez-Lugo, N Goradia, R Gali, LC Shapiro, K Pradhan, ... Cancer cell 39 (8), 1081-1090. e2, 2021 | 324 | 2021 |
| Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality HH Billett, M Reyes-Gil, J Szymanski, K Ikemura, LR Stahl, Y Lo, ... Thrombosis and haemostasis 120 (12), 1691-1699, 2020 | 197 | 2020 |
| Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer LC Shapiro, A Thakkar, ST Campbell, SK Forest, K Pradhan, ... Cancer Cell 40 (1), 3-5, 2022 | 98 | 2022 |
| Assessment of lupus anticoagulant positivity in patients with coronavirus disease 2019 (COVID-19) MR Gil, M Barouqa, J Szymanski, JD Gonzalez-Lugo, S Rahman, ... JAMA network open 3 (8), e2017539-e2017539, 2020 | 98 | 2020 |
| Low ADAMTS13 activity correlates with increased mortality in COVID-19 patients JM Sweeney, M Barouqa, GJ Krause, JD Gonzalez-Lugo, S Rahman, ... TH Open 5 (01), e89-e103, 2021 | 30 | 2021 |
| A case series of monoclonal gammopathy of undetermined significance and COVID‐19 JD Gonzalez‐Lugo, L Bachier‐Rodriguez, M Goldfinger, A Shastri, ... British Journal of Haematology 190 (3), e130, 2020 | 20 | 2020 |
| Natural history and clinical outcomes in patients with portal vein thrombosis by etiology: a retrospective cohort study A Acuna-Villaorduna, V Tran, JD Gonzalez-Lugo, E Azimi-Nekoo, ... Thrombosis Research 174, 137-140, 2019 | 20 | 2019 |
| El impacto socioeconómico del glaucoma primario de ángulo abierto en México JEEGL Martínez, AAM Ibarra, CAR Arpio, LEF Elizondo, JDG Lugo, ... Revista Mexicana de Oftalmología 90 (5), 215-222, 2016 | 20 | 2016 |
| Evidence for secondary thrombotic microangiopathy in COVID-19 JM Sweeney, M Barouqa, GJ Krause, JD Gonzalez-Lugo, S Rahman, ... MedRxiv, 2020 | 18 | 2020 |
| Correlation of coagulation parameters with clinical outcomes during the Coronavirus-19 surge in New York: observational cohort M Reyes Gil, JD Gonzalez-Lugo, S Rahman, M Barouqa, J Szymanski, ... Frontiers in Physiology 12, 618929, 2021 | 13 | 2021 |
| The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia JD Gonzalez-Lugo, S Chakraborty, A Verma, A Shastri Seminars in hematology 58 (1), 56-65, 2021 | 7 | 2021 |
| Correlation of coagulation parameters with clinical outcomes in Coronavirus-19 affected minorities in United States: Observational cohort MR Gil, JD Gonzalez-Lugo, S Rahman, M Barouqa, J Szymanski, ... medRxiv, 2020.05. 01.20087932, 2020 | 7 | 2020 |
| High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination LC Shapiro, A Thakkar, R Gali, JD Gonzalez-Lugo, AH Bazarbachi, ... Leukemia & Lymphoma 63 (10), 2484-2488, 2022 | 6 | 2022 |
| Older age and increased neutrophil-to-lymphocyte ratio (NLR) are predictors of mortality in a multiethnic urban cohort of hematologic neoplasms and COVID-19 patients A D'Aiello, S Zareef, K Pradhan, A Lombardo, F Khatun, J Mustafa, ... Blood 136, 34-35, 2020 | 6 | 2020 |
| Targeting inflammation in lower-risk MDS JD Gonzalez-Lugo, A Verma Hematology 2022 (1), 382-387, 2022 | 5 | 2022 |
| Understanding FLT3 inhibitor resistance to rationalize combinatorial AML therapies A Shastri, J Gonzalez-Lugo, A Verma Blood cancer discovery 2 (2), 113-115, 2021 | 5 | 2021 |
| Lenalidomide and eltrombopag for treatment of low-or intermediate-risk myelodysplastic syndrome: Result of a phase II clinical trial JD Gonzalez-Lugo, S Kambhampati, A Yacoub, WB Donnellan, J Berdeja, ... Clinical Cancer Research 29 (1), 60-66, 2023 | 4 | 2023 |
| Seroconversion rates following COVID-19 vaccination amongst patients with malignant disease-the impact of diagnosis and cancer-directed therapies A Thakkar, JG Lugo, N Goradia, R Gali, LC Shapiro, K Pradhan, ... medRxiv, 2021.05. 07.21256824, 2021 | 4 | 2021 |
| High prevalence of pulmonary findings in computed tomographies of HTLV-1-infected patients with and without adult-T cell leukemia/lymphoma–implications for staging A Acuna-Villaorduna, J Gonzalez-Lugo, BH Ye, DAA Herrera, RA Sica, ... Leukemia & lymphoma, 2019 | 4 | 2019 |
| Lenalidomide and eltrombopag for treatment in low or intermediate risk myelodysplastic syndrome: result of a phase 2 study combination clinical trial JD Gonzalez-Lugo, S Kambhampati, A Yacoub, W Donnellan, P Bhagat, ... Blood 138, 65, 2021 | 3 | 2021 |
